Linesight is delivering scalable infrastructure for two advanced insulin manufacturing facilities as part of a global life sciences programme designed to produce bulk insulin for diabetes treatments, the facilities follow a unified design and execution strategy to ensure consistency and efficiency across regions.
Both projects combined span approximately 85,000 sq.m. and incorporate over 200km of piping. The programme includes more than 100 equipment packages and represents a capital investment of around €3 billion.
The complexity of coordinating two geographically distant sites, managing dual EPCM contractors, and aligning multiple third-party stakeholders was addressed through harmonised processes and governance frameworks, ensuring consistent delivery.
Innovation has been key, with early benchmarking shaping design and cost strategies, BI dashboards enabling real-time reporting, and potential 4D/5D BIM integration enhancing planning and collaboration.